Has Samip Vasaiwala, MD received payments from drug or device companies?

Yes. Drug and device makers reported $125,634 in general payments to Samip Vasaiwala, MD across 215 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Samip Vasaiwala, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Samip Vasaiwala, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Samip Vasaiwala, MD

Cardiovascular Disease · Tampa, FLNPI 1326201773

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (55.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Abbott at 53.7% of the total. 2025 is the largest year on record at $47,336, more than ten times the $905 reported in 2019. Among cardiovascular disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$125,634in general payments, 2019–2025

Across 215 payments — averaging $584.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Abbott$67K
Boston Scientific$29K
Shockwave Medical, Inc$10K
Abiomed$10K
Cardiovascular Systems Inc.$9K
Medtronic$323
plus $615 from 6 others

$76,224in research payments, 2019–2025

Across 23 payments — averaging $3314.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Cardiovascular Systems Inc.$46K
Abbott$28K
Boston Scientific$2K
Abiomed$53

What the payments were for

Consulting fees$33,00026%
Speaking & faculty fees$69,33755%
Travel & lodging$15,91013%
Food & beverage$7,3566%
Gifts$300%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Abbott	97	$67,429
Boston Scientific	40	$29,009
Shockwave Medical, Inc	11	$9,721
Abiomed	27	$9,562
Cardiovascular Systems Inc.	15	$8,975
Medtronic	4	$323
Amgen	14	$252
Asahi Intecc USA, Inc.	2	$186
Heartflow, Inc.	1	$116
Edwards Lifesciences	1	$28
Penumbra, Inc.	2	$26
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	1	$7

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

GENERAL VASCULAR ACCESS$26,854
COROFLOW$23,542
OPTIS$15,284
Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$9,610
PRESSUREWIRE$9,055
Impella$8,689
XIENCE SIERRA$7,423
DRAGONFLY OPSTAR$5,755
Diamondback Coronary$5,507
Dragonfly OCT$4,750
Coronary Orbital Atherectomy System$3,555
GENERAL - THERAPIES$797
AVVIGO Guidance System$612
Diamondback Peripheral$166
ASAHI PTCA Guide Wire$158
COREVALVE EVOLUT R$148
Optis Coronary Imaging System$147
GENERAL - STENTS$131
MAMBA$122
FFRct$116

How this compares

$125,634 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida →

Medicare billing

Part B allowed, 2024

$107,493

Medicare patients

608

Services billed

1,180

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Rosuvastatin Calcium	14	$343

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Tampa

Hiram BezerraTampa$698K
James SmithTampa$324K
David WilsonTampa$258K
Robby WuTampa$190K
Jason FelibertiTampa$138K
Kevin MakatiLutz$1.6M
William OneillNaples$637K
Theodore FeldmanMiami$637K
John Gerald CantoLakeland$588K
Alan MillerJacksonville$547K

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →